Johnson & Johnson (NYSE: JNJ) today announced new long-term data from the QUASAR long-term extension (LTE) study showing that TREMFYA® (guselkumab) sustained clinical, endoscopic, and histologic ...
The property owners who are most successful with SB 721 compliance are those who treat it as an ongoing safety program ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results